33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)

Treatment with remdesivir reduced mortality in a large cohort of hospitalized patients requiring high-flow oxygen, according to a study presented at ECCMID 2023.

Coming down with influenza – commonly called flu – can increase the risk of having a heart attack by sixfold. This is the takeaway from a replication study presented at ECCMID 2023.

For many older adults, functional decline, loss of independence, and ending up in a nursing home is something they dread more than death itself, said Professor Anne Fausley from the University of Rochester School of Medicine, Rochester, New York, US at ECCMID 2023.

The mRNA technology has been researched since the early 60s, with applications not only within the infectious disease space but in rare diseases and respiratory viruses. But the most significant progress has been made during the past decade, said Dr Francesca Ceddia, SVP Respiratory Vaccines, Global Medical, Moderna Inc, at ECCMID 2023.

Among patients with enterobacterales bloodstream infection (BSI), switching from intravenous (IV) to oral antibiotics is noninferior to continuous IV antibiotic therapy in reducing treatment failure within 90 days, according to a study presented at ECCMID 2023.

The use of cloxacillin alone is just as good as the combination of cloxacillin plus fosfomycin in terms of achieving treatment success among hospitalized patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia, according to the results of the open-label, phase IV-III SAFO trial presented at the ECCMID 2023.